CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury

University of Wisconsin (UW)

Status and phase

Enrolling

Phase 2

Conditions

Supra-sacral Spinal Cord Injury

Spinal Cord Injury

Urinary Incontinence

Treatments

Drug: CBD

Study type

Interventional

Funder types

Other

Identifiers

NCT06840899

A539800 (Other Identifier)

Protocol Version 9/16/24 (Other Identifier)

2025-0012

SMPH/UROLOGY/UROLOGY (Other Identifier)

Details and patient eligibility

About

The goal of this feasibility study is to learn whether Cannabidiol (CBD) can improve urinary incontinence and other symptoms in people with recent spinal cord injury (SCI).

Participants will take Epidiolex (purified CBD) for 90 days

Full description

This pilot study assesses the feasibility of using 100mg of twice daily cannabidiol (Epidiolex) in adult spinal cord injury with neurogenic lower urinary tract dysfunction following resolution of spinal shock.

Enrollment

20 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

>18 years of age
History of supra-sacral spinal cord injury of any mechanism
Urinary incontinence with ≥2 episodes of urinary incontinence per day (outside of spinal shock)
Willingness to participate in drug intervention trial
English-speaking (able to provide consent and complete questionnaires)

Exclusion criteria

History of intravesical Botox
Actively taking >15 mg of Oxybutynin single dose or equivalent dose of alternative anticholinergic medication for bladder symptoms
Use of Cannabis (any form) outside of study as determined by urine drug screen after washout period of 1 month if prior Cannabis use reported
Thought or mood disorder aside from depression